MRI在前列腺癌筛查中前景与局限性的关键学习要点
本文总结MRI在前列腺癌筛查中的作用:可降低活检率及惰性癌检出,同时保持高级别癌检出;但阳性预测值低和阅片者间变异大需优化患者选择、成像方案、判读标准、诊断阈值和活检方法。当前证据基于单时间点MRI使用,多轮筛查效果尚不明确。
要点
- MRI用于前列腺癌筛查可减少不必要的活检和惰性癌过度诊断,同时保持高级别癌的有效检出。
- MRI筛查的局限包括阳性预测值低和阅片者间诊断性能变异大,需标准化判读和活检方法。
- 当前证据基于单时间点MRI使用,多轮筛查中MRI有效性尚不明确。
核心结论
- MRI通过降低活检率和惰性癌检出,在旨在发现临床显著前列腺癌的群体筛查研究中保留减少前列腺活检伤害的能力。
- MRI保持对高级别癌的有效检出,从而在有或无血清前列腺特异性抗原(PSA)用于患者选择的群体筛查中改善总体获益-伤害比。
研究设计与样本
- 本文为关于MRI在前列腺癌筛查中前景与局限性的关键学习要点总结,未报告原始研究设计、样本量、中心数或参考标准。
关键影像表现/征象
- 原文未报告具体影像征象或信号特点。
诊断标准与关键数值
- 原文未报告敏感度、特异度、AUC、阈值或分级标准的具体数值。
临床应用与阅片要点
- MRI筛查的局限包括阳性预测值低和阅片者间诊断性能变异大,需在患者选择、成像方案、判读标准、诊断阈值和活检方法方面进行优化。
- 风险计算器和多基因风险评分等新兴技术可能用于选择男性接受MRI,从而提高诊断准确性。
- 人工智能和聚焦于简化诊断路径、质量控制和保证措施的工作流程优化将改善MRI的变异性。
局限性
- MRI筛查的局限包括阳性预测值低和阅片者间诊断性能变异大。
- 当前证据基于单时间点MRI使用,MRI在多轮筛查中的有效性尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
MRI retains its ability to reduce the harm of prostate biopsies by decreasing biopsy rates and the detection of indolent cancers in population-based screening studies aiming to find clinically significant prostate cancers. Limitations of low positive predictive values and high reader variability in diagnostic performance require optimisations in patient selection, imaging protocols, interpretation standards, diagnostic thresholds, and biopsy methods. Improvements in diagnostic accuracy could come about through emerging technologies like risk calculators and polygenic risk scores to select men for MRI. Furthermore, artificial intelligence and workflow optimisations focused on streamlining the diagnostic pathway, quality control, and assurance measures will improve MRI variability. CLINICAL RELEVANCE STATEMENT: MRI significantly reduces harm in prostate cancer screening, lowering unnecessary biopsies and minimizing the overdiagnosis of indolent cancers. MRI maintains the effective detection of high-grade cancers, thus improving the overall benefit-to-harm ratio in population-based screenings with or without using serum prostate-specific antigen (PSA) for patient selection. KEY POINTS: • The use of MRI enables the harm reduction benefits seen in individual early cancer detection to be extended to both risk-stratified and non-stratified prostate cancer screening populations. • MRI limitations include a low positive predictive value and imperfect reader variability, which require standardising interpretations, biopsy methods, and integration into a quality diagnostic pathway. • Current evidence is based on one-time point use of MRI in screening; MRI effectiveness in multiple rounds of screening is not well-documented.
引用
- Padhani AR, Godtman RA, Schoots IG, et al. Key learning on the promise and limitations of MRI in prostate cancer screening. Eur Radiol. 2024. PMID: 38311703. doi:10.1007/s00330-024-10626-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。